NEWS RELEASE

IX BIOPHARMA INTRODUCES MELTMED
A NEW WELLNESS BRAND IN THE UNITED STATES

- Innovative WaferiX Technology is the cornerstone of new health and wellness product line from MeltMed, elevating efficacy
- New products, Regenerate with NAD+ and Radiance with Glutathione, available for Direct-to-Consumer Shipping in the fall

Singapore, 29 September 2023 – iX Biopharma Ltd (the “Company”) (SGX:42C) is pleased to announce that its wholly-owned subsidiary, Meltmed Inc, has introduced its new suite of fast-dissolving wafer products in the United States (the “U.S.”). The new supplements feature nicotinamide adenine dinucleotide (NAD+) and glutathione, which support healthy aging and skin health, respectively, among other functions.

Utilizing the proprietary, breakthrough WaferiX technology, which safely delivers active compounds via the oral mucosal membrane under the tongue, MeltMed products allow for increased absorption and effectiveness – a convenient, discreet and more economical alternative to IV infusions.

MeltMed offers a range of supplement products designed to fight aging at the source. MeltMed's debut offerings in the U.S., which are launching this fall for direct-to-consumer shipping nationwide, are:

- Regenerate with NAD+ - Also known as the "molecule of youth," NAD+ acts as an energy-starter molecule involved in critical biological processes such as cellular energy and cellular repair; reported benefits include converting nutrients into energy and helping to mediate biological processes like rejuvenating aging cells into healthier younger cells. Supports vitality and healthy aging.
- Radiance with Glutathione - Glutathione is the key ingredient, supporting visibly smoother, more radiant, and more supple skin. As the master of all antioxidants and a potent detoxifier, it helps to neutralize free radicals that can damage cells and contribute to aging and boost immunity.

For more information about MeltMed, visit www.meltmed.com.
About iX Biopharma Ltd

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery.

iX Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing which is a growing trend with a global market worth over US$30 billion\(^1\). Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk. iX Biopharma's portfolio includes among others, medicinal cannabis, ketamine, dexmedetomidine sublingual wafers.

Contact for media:

**Eva Tan**  
Chief Commercial Officer  
T: +65 6235 3212  
E: eva.tan@ixbiopharma.com

**Alvina Tan**  
Media & Investor Relations Consultant  
T: +65 9787 7267  
E: alvina.tan@arkadvisors.com.sg

---